Visionary Asset Management Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.2% during the second quarter, Holdings Channel reports. The firm owned 25,825 shares of the company’s stock after selling 2,625 shares during the period. Johnson & Johnson accounts for approximately 1.0% of Visionary Asset Management Inc.’s holdings, making the stock its 17th largest position. Visionary Asset Management Inc.’s holdings in Johnson & Johnson were worth $3,416,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of JNJ. Zurich Insurance Group Ltd FI raised its stake in shares of Johnson & Johnson by 8.0% in the fourth quarter. Zurich Insurance Group Ltd FI now owns 439,086 shares of the company’s stock worth $50,587,000 after buying an additional 32,565 shares during the period. Guardian Capital Advisors LP raised its stake in shares of Johnson & Johnson by 2.5% in the fourth quarter. Guardian Capital Advisors LP now owns 90,314 shares of the company’s stock worth $10,554,000 after buying an additional 2,235 shares during the period. Continental Advisors LLC raised its stake in shares of Johnson & Johnson by 28.9% in the fourth quarter. Continental Advisors LLC now owns 22,300 shares of the company’s stock worth $2,569,000 after buying an additional 5,000 shares during the period. Intact Investment Management Inc. raised its stake in shares of Johnson & Johnson by 7.6% in the fourth quarter. Intact Investment Management Inc. now owns 156,800 shares of the company’s stock worth $18,070,000 after buying an additional 11,100 shares during the period. Finally, Sandhill Capital Partners LLC raised its stake in shares of Johnson & Johnson by 2.7% in the fourth quarter. Sandhill Capital Partners LLC now owns 8,997 shares of the company’s stock worth $1,037,000 after buying an additional 239 shares during the period. Institutional investors and hedge funds own 66.10% of the company’s stock.

Shares of Johnson & Johnson (JNJ) traded up 0.154% during mid-day trading on Tuesday, reaching $133.685. 1,259,754 shares of the company were exchanged. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The firm has a 50-day moving average price of $133.01 and a 200 day moving average price of $126.66. The stock has a market capitalization of $358.81 billion, a P/E ratio of 22.620 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.74 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Position Decreased by Visionary Asset Management Inc.” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-position-decreased-by-visionary-asset-management-inc/1492024.html.

A number of equities research analysts have recently issued reports on JNJ shares. Barclays PLC restated an “equal weight” rating and issued a $130.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a research note on Monday, April 17th. BTIG Research restated a “hold” rating on shares of Johnson & Johnson in a research note on Wednesday, April 19th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $128.54 price objective on the stock in a research note on Monday, April 24th. Jefferies Group LLC reiterated a “hold” rating and set a $135.00 price objective (down previously from $140.00) on shares of Johnson & Johnson in a research note on Sunday, May 14th. Finally, J P Morgan Chase & Co upgraded shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $123.64 to $140.00 in a research note on Monday, May 15th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $133.72.

In related news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.